Posiphen

Pipeline treatments in 7MM prioritize disease-modifying therapies (DMTs) and non-motor symptom therapies for Parkinson’s disease, with 66% of 93 Phase I-III products targeting neuroprotective agents. Key agents include Annovis Bio’s Posiphen and BioVie’s Triolex. Research also focuses on Parkinson’s disease dementia and psychosis, aiming to improve both motor and non-motor symptoms.

Parkinson’s disease (PD) therapeutic landscape lacks neuroprotective and disease-modifying therapies (DMTs). Current treatments focus on motor symptoms, but the pipeline in seven major markets emphasizes DMTs and non-motor symptom therapies. 66% of Phase I-III PD products are neuroprotective agents or DMTs targeting mechanisms like alpha-synuclein aggregation. Key opinion leaders (KOLs) support DMT research, highlighting the need for therapies addressing falls and non-motor symptoms. 18% of the pipeline focuses on symptom management beyond motor symptoms, and 3% targets PD-dementia and PD-psychosis, aiming to address the full spectrum of PD challenges.

Parkinson’s disease (PD) pipeline in 7 major markets emphasizes neuroprotective and disease-modifying therapies (DMTs), with 66% of 93 Phase I-III products targeting mechanisms like alpha-synuclein aggregation. Key opinion leaders (KOLs) support DMT research despite variability in PD pathogenesis, and 18% of the pipeline focuses on non-motor symptoms and postural instability. 3% targets PD-dementia and PD-psychosis, reflecting a comprehensive approach to address both motor and non-motor challenges in PD patients.